31 results about "Pulmonary tuberculosis" patented technology

A molecular marker for drug resistance in Mycobacterium tuberculosis, a reagent kit for detecting drug resistance in Mycobacterium tuberculosis, and a detection method thereof, comprising detecting nonsynonymous mutations at specific gene loci in the pncA gene, rpsA gene, or panD gene, or detecting mutations at specific amino acid loci in the pncA protein, rpsA protein, or panD protein, can help doctors select the most suitable treatment plan for pulmonary tuberculosis, improve the success rate of treatment, reduce the infection and spread of pulmonary tuberculosis, thereby protecting patients and public health.

The utility model discloses an infection department pulmonary tuberculosis protection device relates to medical instrument technical field, including transparent face guard, the right side of transparent face guard front and back part is all fixedly connected with connecting plate, the right side of two connecting plate upper part is all fixedly connected with arc support plate, the right side of two arc support plate is all fixedly connected with fixed bandage, the inner wall fixedly connected with protection subassembly of transparent face guard, the opposite surface fixedly connected with two connecting plates of protection subassembly's outer wall respectively. The utility model discloses an infection department pulmonary tuberculosis protection device, through the effect of protection clothes no.

The utility model relates to the field of medical equipment, and discloses a sputum excretion device for pulmonary tuberculosis nursing, which comprises a sputum excretion device main body, one side of the sputum excretion device main body is fixedly connected with a base, the top of the base is provided with a sputum suction tank, the outer side of the sputum suction tank is provided with a connecting assembly I, and the top of the base is provided with a fixing assembly. A sealing cover is arranged at the top of the sputum suction tank, a second connecting assembly is arranged at the top of the sealing cover and comprises an inlet pipe and an air outlet pipe, the outer side of the inlet pipe and the outer side of the air outlet pipe are both fixedly connected to the interior of the sealing cover, a first groove is formed in the outer side of the inlet pipe, and a second groove is formed in the outer side of the air outlet pipe. According to the sputum suction tube, the convex rings are arranged in the sputum suction tube and the air suction tube, when the sputum suction tube and the air suction tube are connected with the corresponding connectors in an inserted mode, the convex rings in the sputum suction tube and the air suction tube can be clamped in the grooves in the outer sides of the connectors, the air tightness of the connecting positions of the sputum suction tube and the air suction tube is good through interference fit, and the poor sputum suction effect caused by air leakage is avoided.

The invention belongs to the technical field of bioengineering, and particularly provides application of a JNK inhibitor in preparation of drugs for preventing and / or relieving and / or treating pulmonary tuberculosis aiming at the problem that whether the existing JNK inhibitor SP600125 can inhibit BNIP3-mediated mitochondrial autophagy and further exert the ROS bactericidal effect is unknown. And the JNK inhibitor is an SP600125 JNK inhibitor. The JNK inhibitor is used for inhibiting mitochondrial autophagy in the BCG infected macrophages. The JNK inhibitor reduces the up-regulation of BNIP3 and LC3B caused by BCG infection. It is found through the application that when the concentration of the JNK inhibitor reaches 15 umol / L, remarkable cytotoxicity begins to appear, and compared with a control group, the cell survival rate is remarkably decreased. The SP600125 can be used for inhibiting mitochondrial autophagy and down-regulating the expression of BNIP3 and LC3B. Inhibition of JNK expression can inhibit survival of Mtb in RAW264.7 macrophages, and a new thought and direction are provided for treatment of tuberculosis.

The present application relates to a method for increasing the adhesion of a slide, belonging to the technical field of biological medicine, to solve at least one of the problems in the prior art, such as poor adhesion of mycobacterium tuberculosis on the slide, easy to drop the slide in subsequent operation, serious loss of mycobacterium tuberculosis, and influence on the diagnosis rate of pulmonary tuberculosis. The dextromethorphan hydrobromide tablets and the flaxseed gum can generate a high molecular water-soluble polymer with strong positive charge adhesion under the action of a catalyst, that is, the binder described in the present application. Since mycobacterium tuberculosis is the pathogen causing tuberculosis, its surface has a large number of negative charges. Once the mycobacterium tuberculosis with negative charges on the surface contacts the binder containing a large number of positive charges, the surface of the mycobacterium tuberculosis will be quickly wrapped by the binder, forming a firm adhesion layer, and the problem of easy dropping of the slide will not occur during staining and subsequent detection.

The application discloses a kind of pulmonary tuberculosis focus detection method, system and storage medium based on shared feature map, obtains CT image sample;Improvement is carried out based on YOLO neural network model, PA module is used in main network to extract the feature of small pulmonary tuberculosis in CT image;Neck network adds shared feature map CAB and C2f-RFCBAMConv module uses shared feature map to obtain multiple feature information, to obtain the final pulmonary tuberculosis focus feature;And the way of combining NWD and WIou is added to improve the weighting mechanism to adjust the influence degree of different samples. The trained optimized network model is used for focus detection of CT image sample, in order to meet the high demand of detecting small pulmonary tuberculosis and multi-feature information target, the detection sensitivity and positioning accuracy of pulmonary tuberculosis focus are significantly improved, the misdiagnosis rate is effectively reduced, and effective support is provided for clinical diagnosis.

The application provides a method for evaluating the risk of tuberculosis under the combined exposure of extreme weather and air pollution, comprising the steps of: obtaining meteorological data, air pollution data and tuberculosis incidence data of a target area within a target period; identifying extreme weather events based on the meteorological data, identifying air pollution events based on the air pollution data, and identifying combined exposure events based on the meteorological data and the air pollution data, wherein the combined exposure events are combinations of the extreme weather events and the air pollution events that occur within a time interval less than a preset threshold and are spatially co-located; based on the spatial co-location, constructing a regression model with the number of cases in the tuberculosis incidence data as the dependent variable and whether the combined exposure event occurs as the binary explanatory variable, and evaluating the influence of the combined exposure event on the risk of tuberculosis. The application realizes high-precision quantitative evaluation of the risk of tuberculosis under the combined exposure of extreme weather and air pollution, and provides a scientific basis for early warning and precise prevention and control.

1. Name of the product in this design: Packaging Box (Tuberculosis Detection Reagent). 2. Purpose of this design: To hold tuberculosis test reagents. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application relates to an active pulmonary tuberculosis marker and application thereof, the active pulmonary tuberculosis marker is PCBP1, the expression of the PCBP1 in peripheral blood mononuclear cells of an active pulmonary tuberculosis patient is obviously down-regulated, the down-regulated PCBP1 has certain significance for diagnosis of the active pulmonary tuberculosis patient. Moreover, the expression amount of the PCBP1 in the APTB patient is detected by using an RT-qPCR and western blot method, the disease can be diagnosed, and then the active pulmonary tuberculosis diagnosis reagent can be prepared. The application discloses that the PCBP1 can be used as the active pulmonary tuberculosis marker for the first time, and provides a new direction for clinical diagnosis of the active pulmonary tuberculosis.

The application discloses a pulmonary tuberculosis morbidity risk prediction system and application, and is suitable for pulmonary tuberculosis morbidity risk assessment of the elderly. Baseline data of the elderly population meeting the standard are collected, pretreated through cleaning, resampling, coding standardization and the like, a plurality of machine learning models are constructed and performance is compared, a random forest is screened out as an optimal algorithm, 11 core factors of gender, educational level, residence, body mass index BMI, age, occupation, smoking status, complication condition, drinking status, marital status and previous tuberculosis history are selected to construct a model, internal and external verification is carried out, and the model AUC reaches 0.872 and 0.812 respectively, and the calibration degree is good. A prediction system including data collection, analysis and the like units is built based on the model, a Web application tool of a Shiny framework is developed, interactive input of risk factors is realized, morbidity probability is automatically calculated, and three-level risk grading is realized. The application is simple in operation, accurate in prediction, can improve the active screening efficiency of community elderly pulmonary tuberculosis, and provides a scientific tool for accurate prevention and control.

The invention discloses a household aerosol inhalation device for treating pulmonary tuberculosis, and relates to the technical field of medical instruments. The device comprises an atomization assembly, an oxygen supply assembly and a breathing assembly. An atomization main body and a control panel integrated with a vital sign monitoring module are arranged in the atomization assembly; the oxygen supply assembly is detachably arranged on the side wall of the atomization assembly and used for providing and adjusting oxygen. The breathing assembly is simultaneously connected with the atomization pipeline and the oxygen supply pipeline through a connecting seat, and a one-way valve and an inward-concave structure are arranged in the connecting seat and used for guiding inhaled mixed gas and guiding exhaled gas to enter a treatment tank at the bottom end of the mask to be treated. According to the invention, the synchronization of atomization administration and continuous oxygen supply is realized, the bacteria-containing aerosol is filtered from the source through the treatment tank, and the vital sign monitoring function is combined, so that the problems that oxygen therapy needs to be interrupted, the cross infection risk is high and the state of a patient cannot be monitored in real time in traditional treatment are effectively solved, and the safety and effectiveness of treatment are remarkably improved.

The invention relates to a traditional Chinese medicine preparation for treating hydropneumosis and leg and foot edema and a preparation method thereof. The preparation is prepared from 15g of pinellia ternate stems and leaves, 25g of lysimachia christinae hance stems and leaves, 75g of wild pineapple fruits, 3g of fresh ginger and 3g of liquorice. The preparation method comprises the following steps: adding 1500g of water into the medicinal materials, soaking for 10 minutes, boiling with big fire, decocting with small fire until the medicine liquid is concentrated to 500g, filtering, repeatedly decocting once, and combining the two filtrates to obtain 1000g of medicine juice. The medicine juice is taken three times a day in two days, and clinical observation shows that after a patient continuously takes the medicine juice for 4 days, the effusion reduction rate is remarkable. The preparation has the effects of inducing diuresis to reduce edema and promoting effusion discharge, has no obvious toxic or side effect, and is suitable for hydropneumosis and lower limb edema caused by pneumonia, pulmonary tuberculosis, lupus erythematosus and other diseases.

The invention discloses application of a reagent for detecting the content or expression level of TIPE2 in a sample in preparation of a reagent for diagnosing and / or predicting active tuberculosis. In the application, the sample comprises a blood sample. According to the application, the TIPE2 in a blood sample is used as the biomarker for detecting the active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of the TIPE2 in whole blood has good sensitivity and specificity on active tuberculosis diagnosis.

The present application provides siRNA delivery nanomaterials targeting M2 macrophages, which are mannosylated bovine serum albumin nanoparticles encapsulating siRNA interfering with KLK12. The mannose coating of the materials of the present application can provide targeting effect on M2 macrophages, and the siRNA released after endocytosis of the materials can silence the expression of KLK12 and its downstream MMPs genes, reduce the degradation of collagen fibers in lung tissues, thereby controlling the number and volume of pulmonary tuberculosis granulomas, preventing the occurrence of active tuberculosis, and providing a new option for the treatment of tuberculosis.

This invention discloses a respiratory assist device for tuberculosis patients based on motion status, belonging to the field of medical devices. It includes a respiratory assist device with a binding component on one side for securing it to the user's waist. A self-displacement component is mounted on a mounting frame within the binding component, and the respiratory assist device is connected to a sliding frame within the self-displacement component via a connecting component. This application utilizes the binding component to stably secure the entire device to the user's waist, providing a fixed mounting base for the respiratory assist device and ensuring it will not easily detach or shift during user activity. Then, the self-displacement component moves the respiratory assist device mounted on the sliding frame, ultimately precisely adjusting it to a position on the user's lower back. This position better matches the user's breathing rhythm and reduces interference with daily activities.

The application discloses an AI-based medical image X-ray tuberculosis medical information management system, which comprises an image data analysis module, a digital model construction module, a particle dynamic simulation module, a feature focusing extraction module and an auxiliary evaluation output module. The system analyzes target medical images to obtain anatomical structures, respiratory phase states and active lesion areas as a source of dissemination. Accordingly, a personalized lung model is constructed and model parameters including simulated airways and airflow are generated. Then, the diffusion and deposition of biological particles in the bidirectional airflow are simulated from the source of dissemination, and probability distribution data of the dissemination risk are generated. With the data as spatial attention weights, the image is subjected to feature extraction, focusing on detecting small abnormalities in high-risk areas, and generating small lesion detection results. Finally, the probability distribution data and the detection results are fused to output a visual evaluation report. The application significantly improves the recognition ability of small lesions by simulating the disease dissemination mechanism to guide detection.

This invention provides a biomarker for the differential diagnosis of active pulmonary tuberculosis. The biomarker is TRANCE protein. The AUC value of this biomarker for the differential diagnosis of patients with active pulmonary tuberculosis is >0.8, indicating that the biomarker screened by this invention has high diagnostic efficacy for active pulmonary tuberculosis.

The invention discloses a pill formula for treating pulmonary tuberculosis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 2-5 parts of red ginseng, 2-5 parts of American ginseng, 2-5 parts of astragalus membranaceus, 2-5 parts of rhizoma polygonati, 2 parts of codonopsis pilosula, 2 parts of radix ophiopogonis, 2 parts of human placenta, 2 parts of bletilla striata, 2 parts of radix stemonae, 2 parts of radix ranunculi ternati, 1-5 parts of schisandra chinensis, 1-5 parts of sanguisorba officinalis, 1-5 parts of tortoise shell, 1-5 parts of scandent hop, 1 part of scorpion, 1 part of Chinese polyphaga, 1 part of centipede, 1 part of golden cypress, 1 part of cyrtomium fortunei and 1 part of liquorice. Through verification, the pill for treating pulmonary tuberculosis is safe to use and has no adverse side effect. The curative effect is obvious and stable. The traditional Chinese medicine has the advantages of fast effect taking and short treatment course, and can be taken for at least 6 months in general treatment of pulmonary tuberculosis with western medicine, and can be taken for only 3 months to completely cure the pulmonary tuberculosis with anti-tuberculosis medicine for 9 months. As long as the pulmonary tuberculosis is determined, the patient does not need to see a doctor personally and can be easily cured at home according to the description. The treatment cost is lower than that of other therapies.

Provided in the present invention is a biomarker for the differential diagnosis of active pulmonary tuberculosis, wherein the biomarker is a TRANCE protein, and has an AUC value of >0.8 for the differential diagnosis of patients with active pulmonary tuberculosis, indicating that the biomarker screened in the present invention has a relatively high diagnostic efficacy on active pulmonary tuberculosis.

The invention relates to an active tuberculosis diagnostic marker CCND1 and application thereof, in particular to application of a reagent for detecting the diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker CCND1 in a blood sample, and the sequence of the CCND1 is as shown in SEQ ID NO: 1. The CCND1 in a blood sample is adopted as the biomarker for detecting the active tuberculosis for the first time, ROC curve analysis is adopted, the area under the curve (AUC) reaches up to 0.8263, and it is prompted that the mRNA expression level of the CCND1 can be used as an efficient biomarker for distinguishing active TB patients and non-tuberculosis people.

The invention relates to the technical field of diagnostics, and discloses a pulmonary tuberculosis multi-modal fusion diagnosis system, which comprises a data acquisition module, a multi-modal fusion module, an intelligent diagnosis module, an early warning output module and a system management module, uniform format conversion, coding and space-time registration are carried out on multi-source heterogeneous data from image equipment, a laboratory system and clinical records by formulating standardization and alignment rules of multi-modal data, and it is guaranteed that diagnosis information of different sources and different time sequences has a consistent structure and a comparable reference before fusion; and meanwhile, deep features of each modal are deeply integrated through a feature extraction and fusion mechanism, so that feature contradiction and noise interference caused by different data standards and information dislocation can be eliminated, the consistency and reliability of a multi-modal fusion diagnosis information basis are ensured, and diagnosis errors caused by original data quality defects are reduced.

The invention discloses a system and method for diagnosing pulmonary tuberculosis-pulmonary arterial hypertension through artificial intelligence chest CT imaging, and the system comprises a data acquisition module which is used for collecting a chest CT image of a patient in the supine position full inspiration period, and exporting the CT image in a DICOM format; the data processing module is used for carrying out full-lung automatic segmentation and lung lobe segmentation VTDLT calculation by using an AI algorithm through AI image analysis software; the quantitative analysis module is used for outputting the damage volume and the number and distribution of the affected lung lobes; the risk prediction module is used for combining the VTDLT with clinical parameters to construct a PH risk prediction model; according to the application, the pulmonary arterial hypertension is screened by combining CT imaging with an artificial intelligence algorithm, an original mode of screening through right heart catheter examination is not changed, a noninvasive, early-stage and accurate PH screening tool is provided for TDL patients, the use requirements of RHC are reduced, and the pain and medical burden of the patients are relieved.

This invention discloses the use of a combination of nitroimidazole derivatives in the preparation of drugs for the prevention and treatment of drug-resistant tuberculosis, belonging to the field of biomedical technology. This invention fills the clinical research gap regarding the use of combination drugs of nitroimidazole derivatives in the prevention and treatment of drug-resistant tuberculosis, providing a method for its application in the preparation of drugs for this purpose. This invention demonstrates good therapeutic effects against drug-resistant tuberculosis by combining nitroimidazole derivatives with various other anti-tuberculosis drugs, and shows promise as a new drug for the prevention and treatment of drug-resistant tuberculosis.

The utility model belongs to the technical field of medical tools, and particularly relates to a pulmonary tuberculosis bed isolation hood which comprises a transparent bedspread, a first installation opening is formed in the middle of one side wall of the transparent bedspread, a positioning hole is formed in the outer side of the first installation opening, and a first installation assembly penetrates through the inner side of the first installation opening. The first installation assembly comprises a first extrusion ring, an installation groove, a positioning rod and a second extrusion ring, the first extrusion ring is located on one side of the first installation opening, the installation groove is formed in the inner wall of the first extrusion ring, a one-way air inlet valve is clamped to the inner side of the installation groove, and a second installation opening is formed in the edge of the top face of the transparent bedspread. And a second mounting assembly penetrates through the inner side of the second mounting opening, and a fan assembly is clamped to the inner side of the second mounting assembly. In the process of opening the mounting curtain, the fan assembly still sucks and exhausts air, so that the situation that air on the inner side of the bedspread overflows or overflows too much can be avoided, and the isolation effect of the bedspread is improved.

The application discloses a tuberculosis diagnosis circRNA marker, primers and application thereof. The application screens two circRNAs which are significantly highly expressed in PBMC of active pulmonary tuberculosis patients, namely, hsa_circ_0002371, a transcription region of which is located on chromosome 10 and formed by reverse splicing of exons 20 and 21 of a CCAR1 gene, and hsa_circ_0007460, a transcription region of which is located on chromosome 1 and formed by reverse splicing of exons 6-9 of a GOSR1 gene. The application further discloses primers in a tuberculosis diagnosis kit based on the circRNA marker. The circRNA marker can effectively distinguish uninfected people from active pulmonary tuberculosis patients, provides a new thought for studying the pathogenesis of active pulmonary tuberculosis, and provides a new target for early diagnosis of active pulmonary tuberculosis.

The invention relates to a novel coding gene Rv3864c (-4341113-4341511) of mycobacterium tuberculosis H37Rv and a coding protein of the novel coding gene Rv3864c (-4341113-4341511). The Rv3864c gene has high specificity, secretory property and antigenicity, and can be independently or jointly used for clinical rapid screening of latent tuberculosis infected persons and active tuberculosis patients and protecting human bodies from being infected by mycobacterium tuberculosis.

The invention relates to a method for establishing a multi-drug-resistant pulmonary tuberculosis auxiliary diagnosis model based on deep learning and a large model. The method comprises the following steps: S1, automatically marking a CT image of an MDR-PTB patient; s2, image omics feature extraction based on deep learning and a large model; s3, feature screening and radiomics label establishment; and S4, establishing a diagnosis model for early prognosis recognition and judgment of MDR-PTB. According to the method, the disease auxiliary diagnosis model is constructed based on AI + medical image + pre-trained large model, and by means of the technical advantages of AI in sensory cognition and deep learning, the efficiency and accuracy of identifying patients with poor MDR-PTB prognosis are improved, so that clinical diagnosis is assisted, and the probability of missed diagnosis and misdiagnosis is reduced. Meanwhile, through accurate AI image segmentation, the clinical treatment mode and path of MDR-PTB are changed, an optimal treatment scheme is provided according to the specific condition of a patient, adverse reactions of treatment are reduced, and reference is provided for auxiliary decision making of doctors.

The invention relates to a puerarin and berberine hydrochloride eutectic crystal and a preparation method, a composition and application thereof, in the puerarin and berberine hydrochloride eutectic crystal, the molar ratio of puerarin to berberine hydrochloride is 1: 1, the eutectic crystal has higher stability, solubility and bioavailability, and the puerarin and berberine hydrochloride eutectic crystal can be used for preparing a pharmaceutical preparation for preventing and treating diseases. The pharmaceutical composition can be used for treating inflammatory diseases, cardiovascular diseases, diabetes, bacillary dysentery, tuberculosis, scarlet fever, acute tonsillitis or respiratory tract infection.

The invention discloses a pulmonary tuberculosis recognition system based on multi-modal fusion and expert-assisted optimization, which belongs to the technical field of artificial intelligence and comprises a data acquisition module, an imaging examination image, a laboratory examination result and an electronic medical record. The data preprocessing module is used for extracting a first feature by utilizing an iconography examination image, extracting a second feature by utilizing a laboratory examination result and extracting a third feature by utilizing an electronic medical record; the third feature comprises 32 sub-features and contribution degrees corresponding to the sub-features; the optimization module is used for optimizing the contribution degree based on expert diagnosis experience; and the fusion module is used for performing modal fusion on the first feature, the second feature and the optimized third feature to generate a pulmonary tuberculosis recognition result. According to the method, imaging examination images, laboratory examination results and electronic medical records are fused, the contribution degree of expert experience to the features is optimized, intelligent detection of pulmonary tuberculosis is finally achieved, and the method has good generalization ability and pulmonary tuberculosis detection precision.

The present invention relates to the field of biopharmaceutical technology, and in particular, to use of a nitroimidazole derivative or a pharmaceutical combination in the preparation of a medicament against drug-sensitive tuberculosis. Animal studies, phase I and phase II clinical trials, and the optimization of dosage and route of administration have demonstrated that the nitroimidazole derivative has no significant drug accumulation, no significant reproductive toxicity, no significant cardiotoxicity, and no QT prolongation effects. Compared with existing drugs such as delamanid, the nitroimidazole derivative has shorter treatment time, more significant therapeutic effects, and higher safety. Especially in pulmonary images, the cavities in patients are significantly reduced, or the lesions are significantly absorbed, suggesting that the nitroimidazole derivative is promising as a novel drug for preventing and treating drug-sensitive tuberculosis.